Christopher M. Bland

Albert W. Jowdy Professor in Pharmacy Care, University of Georgia College of Pharmacy

About Christopher M. Bland

Dr. Christopher M. Bland is the Albert W. Jowdy Professor in Pharmacy Care at the University of Georgia College of Pharmacy at the Southeast GA campus in Savannah, GA. Dr. Bland has nearly 25 years of academic and clinical experience both in the inpatient and community patient care settings. He is a Fellow of both the Infectious Diseases Society of America as well as the American College of Clinical Pharmacy and has been named Teacher of the Year at the University of Georgia College of Pharmacy. He is co-author of the book "InteGREAT: A Guidebook for Creating Great Healthcare Teams."

He is co-founder of the Southeastern Research Group Endeavor, SERGE-45, with nearly 100 practitioners across 14 states involved. Dr. Bland serves as Associate Editor for the NAPLEX Review Guide 4th edition as well as upcoming 5th edition, as well as the Editor-In-Chief for the Question of the Week. He has provided hundreds of hours in live, interactive NAPLEX reviews for more than 10 Colleges/Schools of Pharmacy over the course of his career. 

Intro Content

Welcome to the NAPLEX® Review Question of the Week: 100th Edition

Today's column will provide some very important news relative to your preparation for the NAPLEX® Review Question of the Week

Popular Content

Recent Comments

Dec 10, 2023

Correct. The first line of the case states that the patient is not pregnant and therefore would be eligible for levofloxacin. 

Oct 06, 2023

Thank you for your input!

Sep 21, 2023

Thank you I added to the question! Fortunately lisinopril is not associated with QTc prolongation. 

Sep 21, 2023

Thank you Angel! I have corrected this as you are correct it should have been fluoxetine. The principle outlined in answer A would apply to either drug as this is true for all SSRIs. 

Sep 11, 2022

It is corrected now thank you. 

Mar 12, 2021

Hi Ahmed- You are correct in that for potent immunosuppressants this would be an issue. Since these are low doses of MTX (< 20mg weekly) they are generally okay. Hope this helps and thanks for your kind words. 

Jan 26, 2021

Hi Faiyaz- Thank you for your inquiry. I went back and rechecked for an interaction with levetiracetam and Ortho Tri Cyclen both within the package insert and using Lexi-Comp software. Both sources found no interaction between the two agents. Ortho tri cyclen can decrease serum concentrations of valproic acid (or divalproex) by approximately 18 and 29% so serum monitoring may be warranted. Therefore I will update this information in question. Thank you.

May 21, 2020

Hi Matthew- Thank you for your question and very sorry for the delay in response as I'm just seeing this. I agree that the inhalation is more of an off-label usage and would not be the most appropriate answer as the exam mainly focuses on "on-label" uses. Therefore I'm going to modify this to just B and C. Thank you for your attention to detail!

Details

Online Elsewhere